Elanco Animal Health (NYSE:ELAN) is at a 52-week high after the company’s first-quarter earnings release. Not only did the animal health company beat consensus expectations, but it also provided ...

Elanco expects fourth-quarter sales of $1 billion—$1.03 billion and adjusted EPS of $0.13-$0.18, compared to the consensus of $1.034 billion and $0.12, respectively.

Elanco Animal Health President and CEO Jeff Simmons said the treatment is a potential blockbuster drug, with potential annual sales of more than $100 million.

Elanco Animal Health Inc. (NYSE:ELAN), a leading player in the animal health industry with a market capitalization of $5.95 billion, has been navigating a complex landscape of product launches ...

Elanco is up 23.2% since the beginning of the year, and at $14.85 per share, it is trading close to its 52-week high of $15.47 from August 2024. Investors who bought $1,000 worth of Elanco’s ...